Anocca is a clinical-stage biopharmaceutical company that develops T-cell receptors to treat infectious and autoimmune diseases.
Anocca has raised $46.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in August 2025.
Anocca's investors include European Investment Bank, AMF, Mellby Gård AB, Swedbank Robur, Ramsbury Invest AB.
Anocca is headquartered in Södertälje, Sweden.
Anocca is a clinical-stage biopharmaceutical company that develops T-cell receptors to treat infectious and autoimmune diseases.
Anocca is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anocca — Funding & Investors." VCBacked, August 18, 2025, https://www.vcbacked.co/company/anocca-sdertlje. Accessed October 22, 2026.
VCBacked. (2025). Anocca — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/anocca-sdertlje
{{cite web |title=Anocca — Funding & Investors |url=https://www.vcbacked.co/company/anocca-sdertlje |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated